Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Late-onset Multiple Sclerosis is associated with an increased rate of reaching Disability Milestones
Multiple Sclerosis
P5 - Poster Session 5 (8:00 AM-9:00 AM)
9-014

To describe patient characteristics and assess the risk of disability worsening measured by the Expanded Disability Status Scale (EDSS) score in patients with late-onset multiple sclerosis (LOMS)

Most patients with multiple sclerosis (MS) have clinical onset between ages 20 and 40 years. However, an increasing proportion of patients are presenting with LOMS, commonly defined as disease onset after the age 50 years. Evidence on the presenting characteristics and the prognosis for these patients is scarce.

The nationwide population-based Danish Multiple Sclerosis Registry served as data source including all patients with available demographic and clinical features. Baseline characteristics were presented using descriptive statistics, as appropriate. Rates of reaching EDSS milestones were analyzed using Cox regression models stratified on baseline EDSS.

We identified 27.615 patients with MS with known year of clinical onset, of which 4678 had LOMS leaving 22.937 with non-LOMS.

In the non-LOMS group the proportion of females was 63.7% compared with 60.7% in the LOMS group. The EDSS at clinical onset was lower in non-LOMS group (2.0) compared with the LOMS group (2.8), while the number of relapses 24 months prior to diagnosis was 2.0 in the non-LOMS group and 1.5 in the LOMS group. The presenting disease course was relapsing-remitting in 90.7% of patients in the non-LOMS group and only 63.9% in the LOMS group.

Patients with LOMS had an increased rate of reaching EDSS milestones of 3 (Hazard ratio (HR): 1.1, 95% Confidence Interval (CI): 0.9-1.4), 4 (HR 1.4, 95% CI: 1.1-1.8), 6 (HR 1.6, 95% CI: 1.2-2.2) and 7 (HR 1.8, 95% CI: 1.0-3.0) when compared to the non-LOMS patients.

Onset of clinical symptoms after the age of 50 years is associated with clinical disease presentation, as well as being an important factor for the risk of EDSS worsening.

Authors/Disclosures
Mads Albrecht Andersen (Danish Multiple Sclerosis Registry)
PRESENTER
An immediate family member of Mr. Andersen has received stock or an ownership interest from Chr. Hansen.
Mathias Buron Mathias Buron has nothing to disclose.
Melinda Magyari, MD Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.